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NATURAL HISTORY AND PROGRESSION OF
PRIMARY CHRONIC VENOUS DISORDER
—Alun H. Davies, MD, Chung S. Lim, MD, London,
United Kingdom
Primary chronic venous disorders (CVDs) refer to
symptoms and signs of venous insufficiency of unknown
origin. Positive family history, increasing age, female gen-
der, pregnancy, and obesity are likely predisposing factors
for the development of CVD (grade: high/systemic review
of population studies).1-6 Common clinical and ultrasono-
graphic scan observations, including the finding of venous
reflux distal to competent valves, presence of competent
valves between varicosities, and venous dilatation preceding
valvular incompetence do not support the descending the-
ory of primary valvular dysfunction (grade: low/ observa-
tional and case control).7-10 These observations are more
likely to be caused by multicentric intrinsic structural and
functional abnormalities of the venous wall which are often
seen in histological specimens (grade: very low/expert’s
opinion).10,11 The ratio of type I to type III collagen is
altered12 and total elastin content is reduced13-16 in vari-
cose vein wall (grade: low/basic science-observational).
The matrix metalloproteases (MMPs) and their tissue in-
hibitors (TIMPs) balance is disrupted leading to extracel-
lular matrix degradation in varicosities (grade: low/basic
science-observational).17-19 Smoothmuscle cells have been
found to dedifferentiate from contractile to synthetic phe-
notype causing decreased contractility of varicosities
(grade: low/basic science-observational).11,20,21 Endothe-
lial cellular injury and activation increase the expression of
inflammatory markers and leukocytes recruitment in vari-
cosities (grade: low/basic science-observational).21-23
Overall, these venous wall changes are thought to contrib-
ute to the weakening, dilatation, and valvular reflux in
varicosities (grade: very low/expert’s opinion).11,18
Chronic venous insufficiency often refers to symptoms and
signs of more severe CVD such as skin changes (eg, eczema
and lipodermatosclerosis) and ulcers. Skin changes and
ulcers are thought to be caused by increased vascular per-
meability leading to extravasation of fibrinogen, 2-macro-
globulin, and erythrocytes into the dermal interstitium
(grade: low/basic science-observational).10,24-28 Degrada-
tion of the interstitial erythrocytes and protein stimulates
chronic injury and inflammatory responses. Increased ex-pression of intercellular adhesion molecule-1 on endothe-
lial cells of the microcirculation recruits macrophages, mast
cells, and lymphocytes (grade: low/basic science-observa-
tional).29,30 Leukocytes in the extracellular space are found
to surround the capillaries and postcapillary venules with
matrix proteins, forming a perivascular cuff (grade: low/
basic science-observational).25,27-32 The cuff is thought to
prevent diffusion of nutrients and oxygen into the dermis,
although it may have a protective role of providing support
to the vascular tissue from increased mechanical stress
(grade: very low/expert’s opinion).10,32 Activated leuko-
cytes are also likely to release more cytokines. The overex-
pression of transforming growth factor-1 by the intersti-
tial leukocytes has been associated with increasing severity
of CVD (grade: low/basic science-observational).33,34
Platelet-derived growth factor receptors- and ) and vas-
cular endothelial growth factor have been found to be
upregulated in the dermis of patients with CVD (grade:
low/basic science-observational).35 The proliferative abil-
ity and collagen production of fibroblasts in the venous
ulcers are reduced compared to those of normal dermis
(grade: low/basic science-observational).36-39 Alteration
to the MMP/TIMP balance such as MMP-1, MMP-2,
MMP-9, TIMP-1, and MT1-MMP has been observed in
the dermis of patients with CVD, indicating active tissue
remodeling (grade: low/basic science-observation-
al).17,34,40-42 There is still limited information on the pro-
gression of primary CVD. In a study of 116 limbs of 90
patients who had at least two duplex ultrasonographic scans
before surgery (median period of 19 months), 31 limbs
(26.7%) were found to have disease progression on the
repeat scan (grade: low/observational/longitudinal).8
Thirteen limbs (11.2%) demonstrated clinical stage pro-
gression (7 from C2-C3; 4 from C3-C4; and 2 from
C4-C6). In another study, 6% (3 of 50 limbs) of patients
with initial C2 to C4 disease developed skin damage after 5
years (grade: low/observational/longitudinal).43 The rate
of disease progression has been shown to be slower in
primary than secondary CVD.43 The mean time for ulcers
to develop from the time of the first CVDdiagnosis is about
5 years (grade: low/observational).44 In conclusion, the
understanding of the natural history and progression of
CVD remains incomplete. Current evidence suggests that
the multifactorial origin of CVD leading to tissue remod-
eling of the venous wall and dermis.
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MANAGEMENT OF PRIMARY VENOUS
DISORDERS IN C6 PATIENTS
—Michel. R. Perrin, MD, Lyon, France
The highest clinical class of venous disorders in the
CEAP classification is C6. To decrease venous ulcer preva-
lence, two steps are necessary: first, healing the ulcer, and
second, preventing its recurrence. It must be kept in mind
that primary etiology is not only identified in the superficial
venous system, but encompasses the perforator and deep
systems, which means that all of the venous system must be
investigated in patients presenting with an ulcer - at least by
